David Loesch

3.6k total citations · 1 hit paper
38 papers, 2.7k citations indexed

About

David Loesch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Loesch has authored 38 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Loesch's work include Cancer Treatment and Pharmacology (20 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (9 papers). David Loesch is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (9 papers). David Loesch collaborates with scholars based in United States, Canada and United Kingdom. David Loesch's co-authors include Lina Asmar, J. Wanders, Joyce O’Shaughnessy, Joanne L. Blum, P. Chollet, Véronique Dièras, Vladimir Vladimirov, Han Koh, Chris Twelves and Javier Cortés and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

David Loesch

38 papers receiving 2.6k citations

Hit Papers

Eribulin monotherapy versus treatment of physician's choi... 2011 2026 2016 2021 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    2011 807 citations Javier Cortés, Joyce O’Shaughnessy et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Loesch United States 16 1.9k 983 834 444 231 38 2.7k
Joyce Steinberg United States 21 980 0.5× 884 0.9× 534 0.6× 503 1.1× 253 1.1× 58 2.6k
Giuseppe Colucci Italy 35 1.3k 0.7× 719 0.7× 402 0.5× 552 1.2× 106 0.5× 152 3.7k
Simona Coco Italy 27 998 0.5× 797 0.8× 717 0.9× 863 1.9× 389 1.7× 102 2.6k
Philippe Bertheau France 26 1.2k 0.7× 357 0.4× 710 0.9× 730 1.6× 174 0.8× 78 2.9k
Rachel Humphrey United States 23 4.2k 2.2× 1.0k 1.1× 607 0.7× 1.0k 2.4× 489 2.1× 50 5.3k
S. M. Steinberg United States 23 1.2k 0.6× 632 0.6× 279 0.3× 935 2.1× 182 0.8× 56 2.5k
G. Fyfe United States 15 1.2k 0.6× 1.0k 1.1× 483 0.6× 820 1.8× 106 0.5× 19 2.7k
Yayi He China 31 2.0k 1.1× 1.1k 1.2× 628 0.8× 1.2k 2.8× 216 0.9× 139 3.7k
Jon M. Wigginton United States 32 2.1k 1.1× 376 0.4× 290 0.3× 823 1.9× 203 0.9× 100 3.5k
Alfons J.M. van den Eertwegh Netherlands 44 2.4k 1.3× 1.2k 1.2× 493 0.6× 1.3k 3.0× 589 2.5× 152 6.0k

Countries citing papers authored by David Loesch

Since Specialization
Citations

This map shows the geographic impact of David Loesch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Loesch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Loesch more than expected).

Fields of papers citing papers by David Loesch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Loesch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Loesch. The network helps show where David Loesch may publish in the future.

Co-authorship network of co-authors of David Loesch

This figure shows the co-authorship network connecting the top 25 collaborators of David Loesch. A scholar is included among the top collaborators of David Loesch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Loesch. David Loesch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weiss, Glen J., Robert P. Whitehead, Ashish Sangal, et al.. (2015). Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. OncoTargets and Therapy. 8. 959–959. 24 indexed citations
2.
Jameson, Gayle, Emanuel F. Petricoin, Jasgit C. Sachdev, et al.. (2014). A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Research and Treatment. 147(3). 579–588. 57 indexed citations
3.
Rudin, Charles M., John T. Poirier, Neil Senzer, et al.. (2011). Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features. Clinical Cancer Research. 17(4). 888–895. 128 indexed citations
4.
Cortés, Javier, Joyce O’Shaughnessy, David Loesch, et al.. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 377(9769). 914–923. 807 indexed citations breakdown →
5.
Bono, Johann S. de, L. Rhoda Molife, Guru Sonpavde, et al.. (2011). Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Annals of Oncology. 23(5). 1241–1249. 44 indexed citations
6.
Hoff, Daniel D. Von, William Sutherland, Mitesh J. Borad, Peter J. Rosen, & David Loesch. (2011). Reply to M. Buyse et al. Journal of Clinical Oncology. 29(15). e453–e453. 2 indexed citations
7.
Richards, Donald, David Loesch, Svetislava J. Vukelja, et al.. (2010). Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. Investigational New Drugs. 29(5). 963–970. 12 indexed citations
8.
Lewis, J J, Matthew D. Galsky, Luis H. Camacho, et al.. (2009). Evaluation of indibulin, a novel tubulin targeting-agent, in combination with capecitabine, with mathematically optimized dose scheduling. Journal of Clinical Oncology. 27(15_suppl). 2538–2538. 1 indexed citations
9.
Detterbeck, Frank C., Mark A. Socinski, Richard J. Gralla, et al.. (2008). Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(1). 37–45. 21 indexed citations
10.
Loesch, David, Lina Asmar, Kristi McIntyre, et al.. (2008). Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 8(2). 178–186. 24 indexed citations
11.
Gralla, Richard J., Martin J. Edelman, Frank C. Detterbeck, et al.. (2008). Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive Care in Cancer. 17(3). 307–313. 14 indexed citations
12.
Robert, Nicholas J., Brian Leyland‐Jones, Lina Asmar, et al.. (2006). Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 24(18). 2786–2792. 342 indexed citations
13.
Berry, William R., et al.. (2006). Phase II Study of Low-Dose Docetaxel/Estramustine in Elderly Patients or Patients Aged 18-74 Years with Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(3). 212–218. 3 indexed citations
14.
15.
Schiller, Joan H., Panos Fidias, Shaker R. Dakhil, et al.. (2005). A phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7142–7142. 1 indexed citations
16.
Berry, William R., James W. Hathorn, Shaker R. Dakhil, et al.. (2004). Phase II Randomized Trial of Weekly Paclitaxel with or Without Estramustine Phosphate in Progressive, Metastatic, Hormone-Refractory Prostate Cancer. PubMed. 3(2). 104–111. 35 indexed citations
17.
Robert, N. J., Brian Leyland‐Jones, Lina Asmar, et al.. (2004). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Journal of Clinical Oncology. 22(14_suppl). 573–573. 28 indexed citations
18.
Loesch, David, Lina Asmar, Gregory A. Parker, et al.. (2003). A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer. Breast Cancer Research and Treatment. 77(2). 115–123. 2 indexed citations
19.
Miller, Kathy D., Nikhil C. Munshi, David Loesch, Lawrence H. Einhorn, & George W. Sledge. (2000). A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma. Cancer. 88(2). 375–380. 4 indexed citations
20.
Miller, Kathy D., Worta McCaskill‐Stevens, David Loesch, et al.. (1999). Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group. Journal of Clinical Oncology. 17(10). 3033–3037. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joyce Steinberg Breakdown of academic impact, for papers by Giuseppe Colucci Breakdown of academic impact, for papers by Simona Coco Breakdown of academic impact, for papers by Philippe Bertheau Breakdown of academic impact, for papers by Rachel Humphrey Breakdown of academic impact, for papers by S. M. Steinberg Breakdown of academic impact, for papers by G. Fyfe Breakdown of academic impact, for papers by Yayi He Breakdown of academic impact, for papers by Jon M. Wigginton Breakdown of academic impact, for papers by Alfons J.M. van den Eertwegh
Rankless by CCL
2026